Stay updated with breaking news from Vivo Program Updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA cleared NTLA-2001 IND application for first in vivo CRISPR candidate to enter late-stage clinical development; on track to initiate the MAGNIT...
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit IND
Completed dose-escalation portion of the ongoing Phase 1 study of NTLA-2001 in patients with transthyretin amyloidosis with cardiomyopathy; expects to present interim safety and serum TTR reduction... | August 4, 2022